CLINICAL RESEARCH: ELECTROPHYSIOLOGY
Hydroquinidine therapy in Brugada syndrome
Jean-Sylvain Hermida, MD*,*,
Isabelle Denjoy, MD  ,
Jérôme Clerc, MD*,
Fabrice Extramiana, MD,
Geneviève Jarry, MD*,
Paul Milliez, MD,
Pascale Guicheney, PhD,
Stefania Di Fusco, MD,
Jean-Luc Rey, MD*,
Bruno Cauchemez, MD and
Antoine Leenhardt, MD
* Amiens-Picardie University Hospital, Amiens, France
Lariboisière University Hospital, Paris, France
Inserm U582, Pitié-Salpêtrière Hospital, Paris, France
Manuscript received October 2, 2003;
revised manuscript received November 22, 2003,
accepted December 9, 2003.
* Reprint requests and correspondence: Dr. Jean-Sylvain Hermida, Service de Cardiologie A, Hôpital Sud, Centre Hospitalier Universitaire d'Amiens-Picardie, 80054 Amiens Cedex, France.
hermida.jean-sylvain{at}chu-amiens.fr
OBJECTIVES: We sought to assess hydroquinidine (HQ) efficacy in selected patients with Brugada syndrome (BrS).
BACKGROUND: Management of asymptomatic patients with BrS and inducible arrhythmias remains a key issue. Effectiveness of class Ia antiarrhythmic drugs, which inhibit the potassium transient outward current of the action potential, has been suggested in BrS.
METHODS: From a cohort of 106 BrS patients, we studied 35 who received HQ (32 men; mean age 48 ± 11 years). Patients had asymptomatic BrS and inducible arrhythmia (n = 31) or multiple appropriate shocks from an implantable cardioverter-defibrillator (ICD) (n = 4). Asymptomatic patients with inducible arrhythmia underwent electrophysiologic (EP)-guided therapy. When ventricular tachycardia (VT)/ventricular fibrillation (VF) inducibility was not prevented, or in case of HQ intolerance, an ICD was placed.
RESULTS: Hydroquinidine prevented VT/VF inducibility in 76% of asymptomatic patients who underwent EP-guided therapy. Syncope occurred in two of the 21 patients who received long-term (17 ± 13 months) HQ therapy (1 syncope associated with QT interval prolongation and 1 unexplained syncope associated with probable noncompliance). In asymptomatic patients who received an ICD (n = 10), one appropriate shock occurred during a follow-up period of 13 ± 8 months. In patients with multiple ICD shocks, HQ prevented VT/VF recurrence in all cases during a mean follow-up of 14 ± 8 months.
CONCLUSIONS: Hydroquinidine therapy prevented VT/VF inducibility in 76% of asymptomatic patients with BrS and inducible arrhythmia, as well as VT/VF recurrence in all BrS patients with multiple ICD shocks. These preliminary data suggest that preventive treatment by HQ may be an alternative strategy to ICD placement in asymptomatic patients with BrS and inducible arrhythmia.
|
Abbreviations and Acronyms
| | BrS | = Brugada syndrome | | ECG | = electrocardiogram | | EP | = electrophysiologic | | HQ | = hydroquinidine | | ICD | = implantable cardioverter-defibrillator | | Ito | = transient outward current | | VF | = ventricular fibrillation | | VT | = ventricular tachycardia |
|
This article has been cited by other articles:
|
|
|
|
 
S. Viskin, C. Antzelevitch, M. F. Marquez, and B. Belhassen
Quinidine: a valuable medication joins the list of 'endangered species'
Europace,
December 1, 2007;
9(12):
1105 - 1106.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Viskin and O. Rogowski
Asymptomatic Brugada syndrome: a cardiac ticking time-bomb?
Europace,
September 1, 2007;
9(9):
707 - 710.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. S. Stokoe, R. Balasubramaniam, C. A. Goddard, W. H. Colledge, A. A. Grace, and C. L.-H. Huang
Effects of flecainide and quinidine on arrhythmogenic properties of Scn5a+/ murine hearts modelling the Brugada syndrome
J. Physiol.,
May 15, 2007;
581(1):
255 - 275.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Viskin
Brugada Syndrome in Children: Don't Ask, Don't Tell?
Circulation,
April 17, 2007;
115(15):
1970 - 1972.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Probst, I. Denjoy, P. G. Meregalli, J.-C. Amirault, F. Sacher, J. Mansourati, D. Babuty, E. Villain, J. Victor, J.-J. Schott, et al.
Clinical Aspects and Prognosis of Brugada Syndrome in Children
Circulation,
April 17, 2007;
115(15):
2042 - 2048.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. S. Stokoe, G. Thomas, C. A. Goddard, W. H. Colledge, A. A. Grace, and C. L.-H. Huang
Effects of flecainide and quinidine on arrhythmogenic properties of Scn5a+/{Delta} murine hearts modelling long QT syndrome 3
J. Physiol.,
January 1, 2007;
578(1):
69 - 84.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Developed in Collaboration With the European Heart, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al.
ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death)
J. Am. Coll. Cardiol.,
September 5, 2006;
48(5):
e247 - e346.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Writing Committee Members, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al.
ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
Europace,
September 1, 2006;
8(9):
746 - 837.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Watanabe, K. Fukushima Kusano, H. Morita, D. Miura, W. Sumida, S. Hiramatsu, K. Banba, N. Nishii, S. Nagase, K. Nakamura, et al.
Low-dose isoproterenol for repetitive ventricular arrhythmia in patients with Brugada syndrome
Eur. Heart J.,
July 1, 2006;
27(13):
1579 - 1583.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. G. Meregalli, A. A.M. Wilde, and H. L. Tan
Pathophysiological mechanisms of Brugada syndrome: Depolarization disorder, repolarization disorder, or more?
Cardiovasc Res,
August 15, 2005;
67(3):
367 - 378.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Antzelevitch, P. Brugada, M. Borggrefe, J. Brugada, R. Brugada, D. Corrado, I. Gussak, H. LeMarec, K. Nademanee, A. R. Perez Riera, et al.
Brugada Syndrome: Report of the Second Consensus Conference: Endorsed by the Heart Rhythm Society and the European Heart Rhythm Association
Circulation,
February 8, 2005;
111(5):
659 - 670.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, O. Ben-Yehuda, D. Berman, G. K. Feld, B. H. Greenberg, J. D. Knoke, K. U. Knowlton, W. Y.W. Lew, J. Narula, D. Sahn, et al.
Highlights of the year in JACC 2004
J. Am. Coll. Cardiol.,
January 4, 2005;
45(1):
137 - 153.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Belhassen, A. Glick, and S. Viskin
Efficacy of Quinidine in High-Risk Patients With Brugada Syndrome
Circulation,
September 28, 2004;
110(13):
1731 - 1737.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
